key: cord-0896528-z56dfjcz authors: Moore, N. A.; Williams, R.; Mori, M.; Bertolusso, B.; Vernet, G.; Lynch, J.; Philipson, P.; Ledgerwood, T.; Kidd, S. P.; Thomas, C.; Garcia-Arias, V.; Young, M.; Saeed, K.; Gordon, K.; Cortes, N. title: Mid-Regional pro-Adrenomedullin (MR-proADM), C-Reactive Protein (CRP) and Other Biomarkers in the Early Identification of Disease Progression in COVID-19 Patients in the Acute NHS Setting date: 2021-04-22 journal: nan DOI: 10.1101/2021.04.19.21252978 sha: 4958ce373326863110c4f4d4b743dab8d6a63446 doc_id: 896528 cord_uid: z56dfjcz Background: There is a lack of biomarkers validated for assessing clinical deterioration in COVID-19 patients upon presentation to secondary or tertiary care. This evaluation looked at the potential clinical application of a range of biomarkers, including C-Reactive Protein (CRP) and Procalcitonin (PCT) and Mid-Regional pro-adrenomedullin (MR-proADM), and White Cell Count to support prediction of clinical outcomes. Methods: Adult patients presenting to Hampshire Hospitals NHS Foundation Trust between April and June 2020 confirmed to have COVID-19 via RT-qPCR were included. Biomarkers were measured in blood samples taken within 24 hours of admission and logistic regression and area under the receiver operating characteristic (AUROC) curves were used to predict disease progression. The endpoints assessed were 30-day all-cause mortality, intubation and ventilation, admission to critical care and non-invasive ventilation (NIV) use. Findings: A total of 135 adult patients were identified. Elevated levels of MR-proADM were shown to have the greatest ability to predict 30-day mortality adjusting for age, cardiovascular disease, renal disease and neurological disease. A significant association was also noted between raised MR-proADM and CRP concentrations and the requirement for critical care admission and non-invasive ventilation, when controlling for covariates. Interpretation: The measurement of biomarkers, particularly MR-proADM and CRP in patients with confirmed COVID-19 infection upon admission to secondary care shows significant potential to support clinicians in the early identification of those at increased risk of disease progression and need for higher level care, subsequently enabling prompt escalation in clinical interventions and treatment. Keywords: MR-proADM, SARS-CoV-2, COVID-19, Mortality, Biomarkers, Emergency Department, 26 Disease progression 27 28 29 Background: There is a lack of biomarkers validated for assessing clinical deterioration in 30 COVID-19 patients upon presentation to secondary or tertiary care. This evaluation looked at 31 the potential clinical application of a range of biomarkers, including C-Reactive Protein 32 (CRP) and Procalcitonin (PCT) and Mid-Regional pro-adrenomedullin (MR-proADM), and 33 White Cell Count to support prediction of clinical outcomes. Methods: Adult patients presenting to Hampshire Hospitals NHS Foundation Trust between 36 April and June 2020 confirmed to have COVID-19 via RT-qPCR were included. Biomarkers 37 were measured in blood samples taken within 24 hours of admission and logistic regression 38 and area under the receiver operating characteristic (AUROC) curves were used to predict 39 disease progression. The endpoints assessed were 30-day all-cause mortality, intubation 40 and ventilation, admission to critical care and non-invasive ventilation (NIV) use. Findings: A total of 135 adult patients were identified. Elevated levels of MR-proADM were 43 shown to have the greatest ability to predict 30-day mortality adjusting for age, 44 cardiovascular disease, renal disease and neurological disease. A significant association 45 was also noted between raised MR-proADM and CRP concentrations and the requirement 46 for critical care admission and non-invasive ventilation, when controlling for covariates. 47 48 Introduction 57 58 Since initial reports of a cluster of pneumonia cases arising from Wuhan, Hubei and the subsequent 59 identification of the causative betacoronavirus, the severe acute respiratory syndrome coronavirus 2 60 (SARS-CoV-2) has infected over 100 million people globally and directly resulted in the deaths of 61 approximately 2.3 million by January 2021. 62 63 The progressive multi-organ failure associated with SARS-CoV-2 mortality is driven in part by 64 significant inflammation and microvascular thrombosis. Presence of SARS-CoV-2 within the 65 endothelium can cause a secondary endotheliitis and an impairment of vascular blood flow, a pro-66 thrombotic state and vascular leakage. (1) During endotheliitis there is elevation of biomarkers, such 67 as neutrophil extracellular traps, that can lead to microvascular thrombosis and inflammation. (2) 68 69 Adrenomedullin is a peptide that has been shown to have a role in preserving the integrity and 70 stability of the endothelium after severe infection. Furthermore, it has potent vasodilatory 71 properties, as well as having a role in immunomodulation and metabolic regulation. It is upregulated 72 in several pathogenic processes, including sepsis and the progression of septic patients towards 73 multi-organ failure(3-5). 74 75 The novel biomarkers mid-regional proadrenomedullin (MR-proADM) has also been shown to be 76 predictive of poor clinical outcomes in patients with sepsis and infections involving the respiratory(6, 77 7) and urinary (8, 9) systems. Similarly, it has been demonstrated during non-infective processes such 78 as heart failure and kidney injury(10). As a precursor amino acid sequence that splits from 79 proadrenomedullin, MR-proADM is used as a surrogate marker for adrenomedullin. It can be 80 measured via an automated immunofluorescent assay, as levels are directly proportional to 81 adrenomedullin which rapidly breaks down in blood. 82 83 The instigation of an appropriate management plan is dependent on an adequate assessment of the 84 infection severity, which is determined by the host pathophysiological response and the virulence of 85 the organism causing infection. adverse outcome over a model incorporating previously identified confounding variables, as outlined 149 above, AUC analyses were compared using a bootstrap method. 150 151 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.19.21252978 doi: medRxiv preprint Samples from 135 patients in total were analysed with a mean age of 64.6 years and a 153 predominance of males (51.9% male vs 48.1% female). The patient group included 105 who had 154 survived by thirty days post admission and 30 who had died by this timepoint. The characteristics of 155 the patient cohort are described in Table 1. 156 157 Median biomarker concentrations in this group showed elevated median CRP 59mg/L (Q1-Q3 range 158 17 -143) and MR-proADM 1.02 nmol/L (Q1-Q3 range 0.71 -1.61); median levels within normal 159 clinical ranges for total white blood cell count 7.1x10 9 /L (Q1-Q3 range 5.2 -9.65), neutrophils 5.31 160 x10 9 /L (Q1-Q3 range 3.51 -7.66) and PCT 0.13ng/mL (Q1-Q3 range 0.07 -0.41) but a suppressed 161 median lymphocyte count 0.98 x10 9 /L (Q1-Q3 range 0. (11) have previously derived and proposed, in a non-COVID-19 174 acute patient population, a cut-off of 1.54 nmol/L as a predictor of elevated mortality, higher rate of 175 ICU admission and longer length of stay. Applying this cut-off to our COVID-19 patient population 176 shows significantly (p = 1.59x10 -5 ) lower mortality rate of 11.11% (N=11) in the patients with MR-177 proADM values < 1.54 nmol/L (N=99 (73.33%)) compared to a higher mortality rate of 52.78% (N=19) 178 in patients (N=36, (26.67%)) with MR-proADM values equal to or exceeding a cut-off of 1.54 nmol/L. 179 None of the patients who died (N=30) had a MR-proADM value below the pre-defined threshold of < 180 0.88 nmol/L (p = 1.61x10 -9 ), previously proposed in a non-COVID-19 population by Saeed et al (11) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. neurological disease (Table 3) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 with Adrenomedullin known to be a regulator of vascular tone and the integrity and stability of the 364 endothelial barrier. 365 366 The early recognition of potential for deterioration in patients infected with SARS-CoV-2 is invariably 367 challenging given the varied clinical course of the disease; particularly with the currently 368 unpredictable potential for deterioration during the second and third weeks of disease. As such, a 369 reliable indicator for early identification of patients at risk of deterioration or a more severe illness 370 trajectory could be of great value, in allowing for earlier targeted intervention or escalation of 371 treatment. 372 373 The study has several limitations. Primarily, a higher event per variable ratio is desirable, fortunately 374 however stratification was only needed for one covariate. Greater power could be achieved through 375 higher participant numbers or through examining serial results over time. A multi-centre study with 376 more patients could also allow for prediction of progression from NIV to intubation. It is a 377 retrospective study; it remains to be seen whether application of such biomarkers into clinical 378 diagnostic and management pathways will deliver the potential expected benefits. Clinician 379 confidence in use of such biomarkers to support decisions has to be developed and evidenced in 380 clinical practice. 381 382 MR-proADM and CRP may have other clinical utility worth exploring, such as whether measurement 383 of these has use in facilitating earlier discharges (11) in individuals with low concentrations or 384 whether a delta change in concentrations could be used to guide decisions on weaning ventilatory 385 support and also the de-escalation or stopping of antibiotics to mitigate against potential future 386 antimicrobial resistance. 387 388 Conclusions 389 Biomarker measurement, in particular MR-proADM, in patients infected with SARS-CoV-2 upon 390 presentation to secondary care shows significant promise in allowing early identification of those at 391 increased risk of disease progression and mortality, possibly providing a tool to support clinical 392 decisions regarding therapeutic interventions and level of care setting. Additionally, adopting use of 393 biomarkers such as MR-proADM in the acute setting carries potential in allowing identification of 394 those at low-risk for severe disease, facilitating discharge decisions. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 22, 2021. The early 453 identification of disease progression in patients with suspected infection presenting to the 454 emergency department: a multi-centre derivation and validation study Relaxing the rule of ten events per variable in logistic and Cox 456 regression Minimum sample size for 458 developing a multivariable prediction model: PART II -binary and time-to-event outcomes Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a 461 randomised, controlled, open-label, platform trial Hydroxychloroquine in Hospitalized Patients with Covid-19 Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a 465 randomised, controlled, open-label, platform trial Biomarkers and clinical scores to aid the identification of disease severity and intensive care 468 requirement following activation of an in-hospital sepsis code Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic 471 administration or intensive care admission 475 tocilizumab-for-hospitalised-patients-patients-with-covid-19-pneumonia-adults/: NHS England and 476 NHS Improvement Interim Clinical Commissioning Policy: Sarilumab for critically ill patients 478 with COVID-19 pneumonia (adults) Adrenomedullin surges are linked to 482 acute episodes of the systemic capillary leak syndrome (Clarkson disease)